Search Results

Press Releases

Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca’s inhaled anti-inflammatory medication Airsupra in asthma patients

October 7, 2024

·

11 min read

Drug Development

Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.

May 20, 2022

·

10 min read

·

Mark Terry

Business

Avillion Appoints Dr Anders Gersel Pedersen, M.D., Ph.D. as Board Member

Avillion LLP announces the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.

September 5, 2019

·

2 min read

Drug Development

Exciting Advancements in Multiple Myeloma, Asthma and Alzheimer’s

Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.

May 16, 2022

·

3 min read

·

Hannah Chudleigh

Drug Development

AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial

October 7, 2024

·

12 min read

Business

Avillion Appoints Dr David Chiswell OBE as Board Member

Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, today announces the appointment of Dr David Chiswell OBE as a Non-Executive Director of Bond 2 Development 2 GP,

March 14, 2019

·

2 min read

FDA

Avillion Announces U.S. Approval of Pfizer’s BOSULIF (bosutinib) for the Treatment of Patients With Newly-Diagnosed Ph+ CML

Avillion announces that the FDA today approved a supplemental sNDA for Pfizer’s BOSULIF (bosutinib).

December 20, 2017

·

5 min read

Business

Avillion Advances Co-Development Programme With Merck: IND Now Open for Phase II Study of M1095, an Anti-IL-17 A/F Nanobody in Psoriasis

Avillion is focused on this collaborative approach to advancing the development of late-stage clinical candidates for pharmaceutical company partners.

February 16, 2018

·

2 min read

Business

Avillion Appoints Kathryn J. Gregory As Chief Business Officer

October 3, 2017

·

1 min read

Business

Avillion Release: Company Strengthens Clinical And Regulatory Development Capabilities With The Appointment Of Mark Weinberg As Chief Medical Officer

January 20, 2017

·

2 min read